Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology.
Giuseppe PattiVeronica LioIlaria CavallariFelice GragnanoLetizia RivaPaolo CalabròGiuseppe Di PasqualeVittorio PengoAndrea Rubbolinull nullPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2020)
In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.
Keyphrases
- respiratory syndrome coronavirus
- coronavirus disease
- sars cov
- cardiovascular events
- cardiovascular disease
- atrial fibrillation
- end stage renal disease
- coronary artery disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- risk factors
- prognostic factors
- venous thromboembolism
- type diabetes
- pulmonary embolism
- patient reported outcomes
- oxidative stress
- bioinformatics analysis